May 21-22, 2012 | Boston, MA

ABOUT THE CONFERENCE

As the governments around the world continue to increase their scrutiny of major corporations, the pharmaceutical industry is coming under heavy pressure from politicians and regulators who are calling for increased transparency from the industry. Although the Sunshine Act reporting requirements have been pushed back into 2012, all companies are preparing or have already begun disclosing their relationships with healthcare professionals, a bold and often controversial step for this highly competitive industry. On a global scale, European governments are now also calling for similar legislation, with countries such as France and the Netherlands most vocally calling for action. As a result, pharmaceutical companies throughout the world are looking to put their compliance programs in place and push forward transparency initiatives that will meet and exceed regulatory requirements.

Through a concise blend of regulatory, industry and legal perspectives, this program will deliver on the promise of helping pharmaceutical companies increase their transparency while maintaining highly productive and professional relationships with government authorities and healthcare professionals. As with all Q1 programs, the networking and knowledge share will be unparalleled.

CLE CREDIT: This conference has been approved for 12 hours of Illinois MCLE credit

| Read More |

TOPICS TO INCLUDE:

• Outlining Accurate Transparency Policies and Procedures for Global Pharma Manufacturers
• Looking Ahead: Aggregate Spend and Transparency Initiatives in the US
• Understanding the International Transparency Landscape
• Outlining New Disclosure Laws in the UK: Bribery and Revised ABPI Code
• Mandatory & Strategic Disclosures for Clinical & Regulatory Filings
• Understanding and Developing Global Communication Systems to Ensure Accurate Transparency
• Defining Best Methods for Capturing Physician Spending Outside Of the US
• Assessing and Determining Fair Market Value on an International Scale
• Moving Beyond the Legal Requirements: Utilizing Transparency Data to Demonstrate Strategic Value
• Understanding Global Requirements for Pharmaceutical Sample Reporting
• Navigating Data Privacy Laws While Maintaining Transparency
• Clarification and Insight into Disclosure and Conflict of Interest Policies
• Developing a Global Approach to Customer Data Management
• Bridging the Gap between Compliance and Aggregate Spend Teams
• Highlighting the Role of Medical Affairs in Transparency
• Transparency Initiatives and Their Affect in HCP Relationships

| And More |

Add to Calendar

KEY PRESENTERS TO INCLUDE:

Jeff Rosenbaum
Chief Compliance Officer
Vertex Pharmaceuticals

Garineh Dovletain
Vice President, Head of Global Contracting & Business Ethics
The Medicines Company

Peter Burberry
Senior Director, Global Practices
Allergan

| And More |